{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:23:13Z","timestamp":1791994993175,"version":"4.4.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenian patients with multidrug-resistant TB predominantly fluoroquinolone-resistant enrolled between 2013 and 2015 in a BDQ compassionate use program. BDQ resistance at baseline and during treatment was assessed using MGIT (pDST\n              <jats:sub>MGIT<\/jats:sub>\n              ), minimal inhibitory concentration in 7H11 (MIC\n              <jats:sub>7H11<\/jats:sub>\n              ), and whole-genome sequencing. Risk factors, such as treatment effectiveness or stage of the disease, were analyzed for association with baseline BDQ resistance, acquired BDQ resistance, and treatment outcome. Among 39 patients, baseline BDQ resistance was 6% (2\/33) by pDST\n              <jats:sub>MGIT<\/jats:sub>\n              and 7% (2\/29) by MIC\n              <jats:sub>7H11<\/jats:sub>\n              . All four baseline isolates with an\n              <jats:italic toggle=\"yes\">Rv0678<\/jats:italic>\n              mutation were phenotypically resistant. During treatment, 48% of the patients acquired BDQ resistance by pDST\n              <jats:sub>MGIT<\/jats:sub>\n              , and 52% acquired mutations at various frequencies (97% in\n              <jats:italic toggle=\"yes\">Rv0678<\/jats:italic>\n              ). None of the factors significantly contributed to baseline or acquired BDQ resistance. Unfavorable treatment outcome (41%) was more frequent in the presence of acquired\n              <jats:italic toggle=\"yes\">Rv0678<\/jats:italic>\n              mutations [odds ratio (OR) 132, 95% confidence interval (CI) 7.43, 2375], phenotypic BDQ resistance (OR 176, 95% CI 6.48, 2423), or MIC increase above or below the critical concentration (both OR 84.3, 95% CI 2.93, 2423) during treatment. For these highly treatment-experienced patients, low baseline prevalence but high incidence of acquired BDQ resistance was observed. Acquisition of mutations in BDQ candidate resistance genes, regardless of their frequency, or increased MICs during treatment, even below the critical concentration, should be seen as a warning sign of resistance amplification and increased risk of unfavorable treatment outcome.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01839-24","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:04:37Z","timestamp":1744203877000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis\u2014experiences from Armenia"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-9194","authenticated-orcid":true,"given":"E.","family":"Ardizzoni","sequence":"first","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]},{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mulders","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Diego Fuertes","sequence":"additional","affiliation":[{"name":"University of Antwerp Faculty of Medicine and Health Sciences","place":["Wilrijk, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hayrapetyan","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Centre of Armenia","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mirzoyan","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Armenia","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Faqirzai","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Khachatryan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Oganezova","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Varaine","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bastard","sequence":"additional","affiliation":[{"name":"Epicentre","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Graulus","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Meehan","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]},{"name":"Nottingham Trent University Clifton Campus","place":["Nottingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-9480","authenticated-orcid":true,"given":"L.","family":"Rigouts","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]},{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decroo","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hewison","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Van Rie","sequence":"additional","affiliation":[{"name":"University of Antwerp Faculty of Medicine and Health Sciences","place":["Wilrijk, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","first-page":"98","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, p 98. World Health Organization, Geneva."},{"key":"e_1_3_4_3_2","first-page":"56","volume-title":"WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis diagnosis","author":"WHO","year":"2020","unstructured":"WHO. 2020. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis diagnosis, p 56"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07861-x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2403.171362"},{"key":"e_1_3_4_6_2","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed","edition":"2"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.01.005"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30031-8"},{"key":"e_1_3_4_9_2","first-page":"1","volume-title":"Critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Matrix","author":"WHO","year":"2018","unstructured":"WHO. 2018. Critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Matrix, p 1\u201310"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","unstructured":"Vargas R Jr Freschi L Spitaleri A Tahseen S Barilar I Niemann S Miotto P Cirillo DM K\u00f6ser CU Farhat MR. 2021. The role of epistasis in amikacin kanamycin bedaquiline and clofazimine resistance in Mycobacterium tuberculosis complex. bioRxiv. doi:10.1101\/2021.05.07.443178","DOI":"10.1101\/2021.05.07.443178"},{"key":"e_1_3_4_11_2","volume-title":"Emergence of bedaquiline resistance after completion of bedaquiline-based drug-resistant TB treatment: a case study from South Africa","author":"Vos de M","year":"2018","unstructured":"Vos de M. 2018. Emergence of bedaquiline resistance after completion of bedaquiline-based drug-resistant TB treatment: a case study from South Africa. Abstract Book ESM Congress, Dresden."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0670"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1002"},{"key":"e_1_3_4_14_2","first-page":"1","volume-title":"Guidelines for the programmatic management of MR TB","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. 2011. Guidelines for the programmatic management of MR TB, p 1\u201344. World Health Organization."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102135"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00037-14"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01462-13"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.081"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00239-17"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0840"},{"key":"e_1_3_4_21_2","unstructured":"World Health Organization. 2019. WHO consolidated guidelines on drug-resistance TB treatment"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002884"},{"key":"e_1_3_4_23_2","unstructured":"World Health Organization. 2014. Definitions and reporting framework for tuberculosis"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011648"},{"key":"e_1_3_4_25_2","first-page":"97","volume-title":"Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections\u2014a systematic review and meta-analysis","author":"Diaz R","year":"2018","unstructured":"Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. 2018. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections\u2014a systematic review and meta-analysis, Vol. 24, p 97\u2013104. Vol. 24. Clinical Microbiology and Infection. Elsevier B.V."},{"key":"e_1_3_4_26_2","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Global tuberculosis report 2023"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00470-9"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002283"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.4103\/2212-5531.307132"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw502"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02383-2019"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1815121"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01677-19"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2019.05.001"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00803-09"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01839-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01839-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:02:10Z","timestamp":1746622930000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01839-24"}},"subtitle":[],"editor":[{"given":"Jared A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,7]]}},"alternative-id":["10.1128\/aac.01839-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01839-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01839-24"}}